title: Discontinuation of quetiapine from an NIMH-funded trial due to serious adverse events.
authors: Dilip V
authors: DV
authors: Jeste
authors: Hua
authors: H
authors: Jin
authors: Shahrokh
authors: S
authors: Golshan
authors: Sunder
authors: S
authors: Mudaliar
authors: Danielle
authors: D
authors: Glorioso
authors: Ian
authors: I
authors: Fellows
authors: Helena
authors: H
authors: Kraemer
authors: Stephan
authors: S
authors: Arndt
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009315:National Institute of Mental Health (U.S.) / Q000706:statistics & numerical data; D000069348:Quetiapine Fumarate; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D012044:Regression Analysis; D012109:Research Support as Topic / Q000706:statistics & numerical data; D014481:United States
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate